Eligo Bioscience Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
2ndary - Private
- Investors
-
13
Eligo Bioscience General Information
Description
Developer of antibiotics designed to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine sequencing systems with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling pharmaceutical companies to make medicines from pathogen-resistant antimicrobials.
Contact Information
Website
www.eligo.bioCorporate Office
- 111 Avenue De France
- 75013 Paris
- France
Corporate Office
- 111 Avenue De France
- 75013 Paris
- France
Eligo Bioscience Timeline
Eligo Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 17. Secondary Transaction - Private | 01-Apr-2026 | Completed | Generating Revenue | |||
| 16. Grant | 14-May-2025 | Completed | Generating Revenue | |||
| 15. Later Stage VC (Series B) | 03-May-2024 | Completed | Generating Revenue | |||
| 14. Accelerator/Incubator | 01-Jan-2022 | Completed | Generating Revenue | |||
| 13. Grant | 30-Jun-2020 | Completed | Generating Revenue | |||
| 12. Grant | 01-May-2019 | Completed | Generating Revenue | |||
| 11. Grant | 01-Jan-2019 | Completed | Generating Revenue | |||
| 10. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 9. Early Stage VC (Series A) | 26-Sep-2017 | $16.9M | $19M | Completed | Generating Revenue | |
| 8. Accelerator/Incubator | 01-Jan-2017 | $2.16M | Completed | Generating Revenue |
Eligo Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| B | ||||||||
| A | 266,666 | $0.047727 | $8.95 | $8.95 | 1x | $8.95 | 11.97% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Eligo Bioscience Comparisons
Industry
Financing
Details
Eligo Bioscience Competitors (48)
One of Eligo Bioscience’s 48 competitors is Vedanta Biosciences, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| NovaBiotics | Venture Capital-Backed | Aberdeen, United Kingdom | ||||
| Gangagen Biotechnologies | Venture Capital-Backed | Bangalore, India | ||||
| Enterome | Venture Capital-Backed | Paris, France | ||||
| 4D pharma | Corporation | Leeds, United Kingdom |
Eligo Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Eligo Bioscience Patents
Eligo Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4750918-A1 | Detection and treatment of c. acnes bacteria-associated diseases | Pending | 24-Jul-2023 | ||
| WO-2025021861-A1 | Detection and treatment of c. acnes bacteria-associated diseases | Inactive | 24-Jul-2023 | ||
| US-12414962-B2 | Method for treating c. acnes bacteria-associated diseases | Active | 24-Jul-2023 | ||
| US-20250032528-A1 | Method for treating c. acnes bacteria-associated diseases | Active | 24-Jul-2023 | ||
| US-20250381212-A1 | Method for treating c. acnes bacteria-associated diseases | Pending | 24-Jul-2023 | A61K31/7088 |
Eligo Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Eligo Bioscience Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Sanofi Ventures | Corporate Venture Capital | Minority | ||
| Vives Fund | Venture Capital | Minority | ||
| Termeer Institute | Accelerator/Incubator | |||
| CARB-X | University | |||
| European Commission | Government |
Eligo Bioscience FAQs
-
When was Eligo Bioscience founded?
Eligo Bioscience was founded in 2014.
-
Where is Eligo Bioscience headquartered?
Eligo Bioscience is headquartered in Paris, France.
-
What is the size of Eligo Bioscience?
Eligo Bioscience has 46 total employees.
-
What industry is Eligo Bioscience in?
Eligo Bioscience’s primary industry is Drug Discovery.
-
Is Eligo Bioscience a private or public company?
Eligo Bioscience is a Private company.
-
What is Eligo Bioscience’s current revenue?
The current revenue for Eligo Bioscience is .
-
How much funding has Eligo Bioscience raised over time?
Eligo Bioscience has raised $56.5M.
-
Who are Eligo Bioscience’s investors?
Sanofi Ventures, Vives Fund, Termeer Institute, CARB-X, and European Commission are 5 of 13 investors who have invested in Eligo Bioscience.
-
Who are Eligo Bioscience’s competitors?
Vedanta Biosciences, NovaBiotics, Gangagen Biotechnologies, Enterome, and 4D pharma are some of the 48 competitors of Eligo Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
